Plain-English translation of NCT07202143 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether —a type of steroid medication—can improve survival and recovery when given quickly during emergency treatment for severe strokes. Participants will receive this medication (or a placebo) as part of their emergency blood clot removal procedure. The research focuses on stroke patients who have large areas of brain damage and changes in their immune system that may make recovery harder.
Patients who have severe strokes with large areas of brain damage often have weakened immune systems, which puts them at higher risk of death and poor recovery. Currently, there are very few treatment options available to help these patients, so this trial is testing whether giving this medication early might improve their chances of survival and better recovery.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either the steroid medication or a placebo injection as part of your emergency stroke treatment during blood clot removal. You will be randomly assigned to one group or the other, and neither you nor your doctors will know which you received. After treatment, you will be followed for 90 days with check-ins to monitor your recovery, survival, and overall function—these may include hospital visits, phone calls, or assessments of how well you can perform daily activities.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
China